Dr. Andrew Karim Abdel Kader, MD

Dr. Kader practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Kader's NPI, 1184731127, was assigned on August 24, 2006. Dr. Kader graduated from University of British Columbia in 2000. Dr. Kader holds California license A116234.

Dr. Kader's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Kader's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Kader is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kader practices. Vendor and product names are available with a free account.

Urology is Dr. Kader's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Kader is board certified in urology by the American Board of Urology. Dmand AI has Dr. Kader's licenses on file in 4 states: California, North Dakota, North Carolina and Texas.

Dmand AI lists bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney stone disease, prostate cancer and prostate surgery among the conditions Dr. Kader treats.

CMS data shows 527 Medicare services from Dr. Kader across 6 procedure codes in 2024, for 306 Medicare patients. Medicare paid $41,905 for them.

CMS counts 306 Medicare patients who saw Dr. Kader in 2024. The largest group is 65 to 74, with 131 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kader's median patient age at 72, with 17% women.

In 2024, Dr. Kader wrote 283 Medicare Part D claims for 114 patients. 90% of them were for generic drugs. CMS names the drug for 228 of them, across 7 drugs with 11 or more claims each, at $25,132 in total drug cost. In 2023, CMS named 175 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Kader for performance year 2024, reported as part of a group. Dr. Kader accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kader as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 46 papers to Dr. Kader, published from 2010 to 2024. 2013 was the busiest year, with 4. The most frequent topics are Prostatic Neoplasms, Prostate-Specific Antigen and Urinary Bladder Neoplasms. Dr. Kader has published most often in Urology. Dr. Kader's most frequent co-authors are Christopher J. Kane, MD, John Kellogg Parsons, MD and Brent Shane Rose, MD.

Dmand AI links Dr. Kader to 1 clinical trial.

CMS Open Payments shows 151 general payments to Dr. Kader from 29 drug and device companies from 2016 to 2025. Education make up the largest share, 51% of the total. Olympus Corporation of the Americas paid the most, $8,388.

Dmand AI lists 1 award for Dr. Kader, most recently CMS Stage 1 EHR in 2013.

Dr. Kader graduated from University of British Columbia in 2000.

Dr. Kader is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.